Effect of vitamin D supplementation in regulation of blood pressure in essential hypertensive patients
Design
This study is a single-center, prospective, open-labeled,parallel phase 3 clinical trial.
Settings and conduct
Patients who visit the Baqiyatallah Hospital Clinic, which meets the inclusion criteria, will be divided into two intervention groups, based on vitamin D level.
Participants/Inclusion and exclusion criteria
Inclusion Criteria:
Essential Hypertension (Systolic pressure > 140 mmHg, Diastolic pressure > 90 mmHg)
Adult patients from 18 to 65 y/o
Patients under standard Anti-hypertensive agents
Vitamin D serum level less than 30.
Exclusion Criteria
Heart Failure (LVEF<45%)
Renal Failure (Creatinine>1.5mg/dl)
Hepatic Failure
Chronic Obstructive Pulmonary Disease (COPD): (FEV1/FVC <70%)
Thyroid disorders
Hyperparathyroidism
Systemic infection
Hypercalciurea
Intervention groups
Intervention arm 1 : 5000 U vitamin D until 8 weeks (in addition to routine anti hypertensive drugs);
intervention arm 2: 1000 U vitamin D until 8 weeks (in addition to routine anti hypertensive drugs)
Chemical Injuries Research Center, Baqiyatallah University of Medical sciences
Expected recruitment start date
2014-10-23, 1393/08/01
Expected recruitment end date
2015-06-09, 1394/03/19
Actual recruitment start date
2014-10-23, 1393/08/01
Actual recruitment end date
2015-06-22, 1394/04/01
Trial completion date
2015-06-22, 1394/04/01
Scientific title
Investigating the effect of vitamin D3 supplementation in blood pressure control in essential hypertensive patients
Public title
Effect of vitamin D supplement in regulation of blood pressure
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Essential Hypertension (Systolic pressure > 140 mmHg, Diastolic pressure > 90 mmHg)
Adult patients from 18 to 65 y/o
Patients under standard Anti-hypertensive agents
Vitamin D level is less than 30.